Investor Vijay Kedia's savvy investment in Neuland Laboratories has paid off handsomely, yielding nearly 100x returns. He seized the opportunity during the Covid downturn when stock prices dipped. By concentrating on the company’s promising peptide sector and its CDMO capabilities, Kedia emphasized his tactic of investing in overlooked firms with solid fundamentals, which has ultimately fostered substantial wealth growth over the years.
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.